IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
OPTIMAL: Phase III Study of First-line Erlotinib Versus Gemcitabine Plus Carboplatin (GC) in Chinese Patients (pts) With Activating EGFR Mutation-Positive Advanced Non-small Cell Lung Cancer (NSCLC). On behalf of the OPTIMAL Investigators
Wang, J.1; Zhou, C.2; Wu, Y.3; Lu, S.4; Zhang, L.5; Zhang, Y.6; Ye, M.7; Ma, J.8; Huang, J.9; Xiu, Q.10
刊名JOURNAL OF THORACIC ONCOLOGY
2010-12-01
suppl.7期:12页:S507-S508
收录类别SCI
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Oncology ; Respiratory System
研究领域[WOS]Oncology ; Respiratory System
语种英语
WOS记录号WOS:000284994100019
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64002
专题北京大学临床肿瘤学院
作者单位1.Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
2.Zhejiang Canc Hosp, Hangzhou, Peoples R China
3.Harbin Inst Hematol & Oncol, Harbin, Peoples R China
4.Suzhou Univ, Affiliated Hosp 1, Suzhou 215006, Peoples R China
5.Peking Univ, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
6.Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
7.Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
8.Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 200030, Peoples R China
9.Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai 200030, Peoples R China
10.Second Mil Med Univ, Changzhen Hosp, Shanghai, Peoples R China
推荐引用方式
GB/T 7714
Wang, J.,Zhou, C.,Wu, Y.,et al. OPTIMAL: Phase III Study of First-line Erlotinib Versus Gemcitabine Plus Carboplatin (GC) in Chinese Patients (pts) With Activating EGFR Mutation-Positive Advanced Non-small Cell Lung Cancer (NSCLC). On behalf of the OPTIMAL Investigators[J]. JOURNAL OF THORACIC ONCOLOGY,2010,suppl.7(12):S507-S508.
APA Wang, J..,Zhou, C..,Wu, Y..,Lu, S..,Zhang, L..,...&Xiu, Q..(2010).OPTIMAL: Phase III Study of First-line Erlotinib Versus Gemcitabine Plus Carboplatin (GC) in Chinese Patients (pts) With Activating EGFR Mutation-Positive Advanced Non-small Cell Lung Cancer (NSCLC). On behalf of the OPTIMAL Investigators.JOURNAL OF THORACIC ONCOLOGY,suppl.7(12),S507-S508.
MLA Wang, J.,et al."OPTIMAL: Phase III Study of First-line Erlotinib Versus Gemcitabine Plus Carboplatin (GC) in Chinese Patients (pts) With Activating EGFR Mutation-Positive Advanced Non-small Cell Lung Cancer (NSCLC). On behalf of the OPTIMAL Investigators".JOURNAL OF THORACIC ONCOLOGY suppl.7.12(2010):S507-S508.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, J.]的文章
[Zhou, C.]的文章
[Wu, Y.]的文章
百度学术
百度学术中相似的文章
[Wang, J.]的文章
[Zhou, C.]的文章
[Wu, Y.]的文章
必应学术
必应学术中相似的文章
[Wang, J.]的文章
[Zhou, C.]的文章
[Wu, Y.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。